phytomenadione 🐶 Veterinary Use | Indications/Contra | FAERs-F | FAERs-M | Orange Bk | BioActivity |

Stem definition	Drug id	CAS RN
	2843	84-80-0

Description:

Molecule	Description
Molfile Inchi Smiles Synonyms: vitamin K1 phytomenadione vitamin K phytonadione phytylmenadione phytylmenaquinone phylloquinone	A lipid cofactor that is required for normal blood clotting. Several forms of vitamin K have been identified: VITAMIN K 1 (phytomenadione) derived from plants, VITAMIN K 2 (menaquinone) from bacteria, and synthetic naphthoquinone provitamins, VITAMIN K 3 (menadione). Vitamin K 3 provitamins, after being alkylated in vivo, exhibit the antifibrinolytic activity of vitamin K. Green leafy vegetables, liver, cheese, butter, and egg yolk are good sources of vitamin K. Molecular weight: 450.71 Formula: C31H46O2 CLOGP: 11.69 LIPINSKI: 1 HAC: 2 HDO: 0 TPSA: 34.14 ALOGS: -6.88 ROTB: 14 Status: OFP Legend: OFP - off patent OFM - off market ONP - on patent

Molecule

Description

Molfile Inchi Smiles

Synonyms:

vitamin K1
phytomenadione
vitamin K
phytonadione
phytylmenadione
phytylmenaquinone
phylloquinone

A lipid cofactor that is required for normal blood clotting. Several forms of vitamin K have been identified: VITAMIN K 1 (phytomenadione) derived from plants, VITAMIN K 2 (menaquinone) from bacteria, and synthetic naphthoquinone provitamins, VITAMIN K 3 (menadione). Vitamin K 3 provitamins, after being alkylated in vivo, exhibit the antifibrinolytic activity of vitamin K. Green leafy vegetables, liver, cheese, butter, and egg yolk are good sources of vitamin K.

Molecular weight: 450.71
Formula: C31H46O2
CLOGP: 11.69
LIPINSKI: 1
HAC: 2
HDO: 0
TPSA: 34.14
ALOGS: -6.88
ROTB: 14

Status: OFP

Legend:
OFP - off patent
OFM - off market
ONP - on patent

Drug dosage:

Dose	Unit	Route
20	mg	O
20	mg	P

ADMET properties:

Property	Value	Reference
Vd (Volume of distribution)	0.32 L/kg	Lombardo F, Berellini G, Obach RS
CL (Clearance)	1.60 mL/min/kg	Lombardo F, Berellini G, Obach RS
t_half (Half-life)	7.30 hours	Lombardo F, Berellini G, Obach RS

Approvals:

Date	Agency	Company	Orphan
May 18, 2000	FDA	SANDOZ

FDA Adverse Event Reporting System (Female)

MedDRA adverse event term	Likelihood ratio	Likelihood ratio threshold	Patients taking drug having adverse event	Patients taking drug not having adverse event	Patients not taking drug having adverse event	Patients not taking drug not having adverse event
Infective pulmonary exacerbation of cystic fibrosis	199.28	14.53	67	8178	7842	50589037
International normalised ratio increased	71.58	14.53	58	8187	43094	50553785
Multiple organ dysfunction syndrome	52.36	14.53	52	8193	50285	50546594
Cystic fibrosis	51.91	14.53	19	8226	2845	50594034
Ascites	46.77	14.53	42	8203	35819	50561060
Renal vascular thrombosis	46.51	14.53	8	8237	46	50596833
Coagulopathy	45.17	14.53	31	8214	17913	50578966
Factor V inhibition	37.08	14.53	8	8237	168	50596711
Injury associated with device	36.31	14.53	15	8230	3102	50593777
Cholestasis	35.61	14.53	31	8214	25370	50571509
Sepsis	33.92	14.53	70	8175	132855	50464024
Osteochondritis	30.00	14.53	5	8240	23	50596856
Haematemesis	27.63	14.53	28	8217	27697	50569182
Intestinal dilatation	27.58	14.53	10	8235	1458	50595421
Pancreatitis chronic	26.93	14.53	11	8234	2209	50594670
Thrombocytopenia	26.62	14.53	62	8183	127611	50469268
Superior sagittal sinus thrombosis	26.04	14.53	8	8237	699	50596180
Hepatic failure	25.80	14.53	29	8216	32254	50564625
Haemorrhage neonatal	25.80	14.53	5	8240	60	50596819
Premature baby	24.93	14.53	22	8223	18315	50578564
Transverse sinus thrombosis	23.94	14.53	7	8238	517	50596362
Acute hepatic failure	23.73	14.53	20	8225	15657	50581222
Haemoptysis	22.21	14.53	24	8221	25549	50571330
Prothrombin time prolonged	21.60	14.53	15	8230	8823	50588056
Neonatal anuria	21.13	14.53	4	8241	42	50596837
Necrotising enterocolitis neonatal	21.13	14.53	5	8240	161	50596718
Respiratory failure	20.91	14.53	46	8199	91135	50505744
Vitamin K deficiency	20.87	14.53	6	8239	417	50596462
Activated partial thromboplastin time prolonged	20.85	14.53	13	8232	6389	50590490
Blood alkaline phosphatase increased	20.75	14.53	28	8217	37498	50559381
Acute respiratory distress syndrome	20.46	14.53	21	8224	21078	50575801
Acute kidney injury	20.19	14.53	82	8163	227976	50368903
Drug intolerance	19.05	14.53	6	8239	219098	50377781
Terminal ileitis	18.70	14.53	6	8239	605	50596274
Rheumatoid arthritis	18.61	14.53	5	8240	202545	50394334
HER2 positive breast cancer	18.01	14.53	5	8240	306	50596573
Gamma-glutamyltransferase increased	17.76	14.53	23	8222	29600	50567279
Hypokalaemia	17.53	14.53	42	8203	87950	50508929
Cytokine release syndrome	17.32	14.53	13	8232	8621	50588258
Pelvic fluid collection	17.24	14.53	6	8239	777	50596102
Oligohydramnios	17.04	14.53	11	8234	5739	50591140
Pulmonary pain	16.82	14.53	8	8237	2307	50594572
Pulmonary function test decreased	16.68	14.53	9	8236	3379	50593500
Aspartate aminotransferase increased	16.37	14.53	38	8207	77960	50518919
Pain	16.17	14.53	45	8200	578858	50018021
Hepatic encephalopathy	16.06	14.53	13	8232	9623	50587256
Jugular vein thrombosis	15.66	14.53	8	8237	2688	50594191
Foetal growth restriction	15.62	14.53	11	8234	6616	50590263
Suspected transmission of an infectious agent via product	14.55	14.53	4	8241	236	50596643

FDA Adverse Event Reporting System (Male)

MedDRA adverse event term	Likelihood ratio	Likelihood ratio threshold	Patients taking drug having adverse event	Patients taking drug not having adverse event	Patients not taking drug having adverse event	Patients not taking drug not having adverse event
Appendicolith	245.13	15.04	76	9545	3404	29561502
Infective pulmonary exacerbation of cystic fibrosis	187.27	15.04	72	9549	6164	29558742
Ascites	183.79	15.04	126	9495	36493	29528413
Appendicitis	179.81	15.04	77	9544	8702	29556204
Cardiogenic shock	138.31	15.04	83	9538	19107	29545799
Multiple organ dysfunction syndrome	129.22	15.04	129	9492	62987	29501919
Stress	114.98	15.04	77	9544	21413	29543493
Abdominal distension	105.46	15.04	100	9521	45811	29519095
Toxic epidermal necrolysis	67.14	15.04	52	9569	18101	29546805
Sepsis	67.09	15.04	145	9476	142537	29422369
Hyponatraemia	66.24	15.04	95	9526	67538	29497368
International normalised ratio increased	64.88	15.04	76	9545	44296	29520610
Abdominal pain	60.71	15.04	135	9486	135222	29429684
Cystic fibrosis	43.95	15.04	17	9604	1475	29563431
Ventricular fibrillation	43.15	15.04	38	9583	15795	29549111
Hepatic failure	42.78	15.04	52	9569	31460	29533446
Hyper IgE syndrome	39.76	15.04	8	9613	55	29564851
General physical health deterioration	37.79	15.04	95	9526	102762	29462144
Constipation	37.40	15.04	101	9520	114059	29450847
Vomiting	31.93	15.04	145	9476	212115	29352791
Epileptic encephalopathy	24.20	15.04	6	9615	115	29564791
Hyperbilirubinaemia	24.19	15.04	27	9594	14907	29549999
Hepatic encephalopathy	23.62	15.04	25	9596	13010	29551896
Acute hepatic failure	23.59	15.04	24	9597	11928	29552978
Hyphaema	23.52	15.04	8	9613	480	29564426
Cystic fibrosis related diabetes	23.17	15.04	6	9615	138	29564768
Death	22.30	15.04	49	9572	342035	29222871
Activated partial thromboplastin time prolonged	21.93	15.04	19	9602	7723	29557183
Toxicity to various agents	20.40	15.04	16	9605	173645	29391261
Cortical visual impairment	20.21	15.04	4	9617	25	29564881
Coagulation time prolonged	19.56	15.04	9	9612	1201	29563705
Coagulopathy	18.74	15.04	26	9595	17881	29547025
Prothrombin time prolonged	17.91	15.04	18	9603	8814	29556092
Blood bilirubin increased	17.66	15.04	36	9585	33857	29531049
Myocardial infarction	17.48	15.04	7	9614	110289	29454617
Iatrogenic infection	17.12	15.04	4	9617	59	29564847
Drug ineffective	16.99	15.04	61	9560	363109	29201797
Skin candida	16.67	15.04	6	9615	426	29564480
Respiratory failure	15.78	15.04	68	9553	97063	29467843
Genital herpes	15.14	15.04	6	9615	555	29564351
Dizziness	15.12	15.04	24	9597	189660	29375246

FDA Adverse Event Reporting System (Geriatric)

MedDRA adverse event term	Likelihood ratio	Likelihood ratio threshold	Patients taking drug having adverse event	Patients taking drug not having adverse event	Patients not taking drug having adverse event	Patients not taking drug not having adverse event
Infective pulmonary exacerbation of cystic fibrosis	344.46	14.10	124	15810	11672	64471126
Appendicolith	265.90	14.10	76	15858	3393	64479405
Ascites	222	14.10	156	15778	61845	64420953
Multiple organ dysfunction syndrome	177.39	14.10	168	15766	101245	64381553
Appendicitis	167.86	14.10	77	15857	13492	64469306
Cardiogenic shock	138.36	14.10	91	15843	32336	64450462
International normalised ratio increased	117.57	14.10	120	15814	79047	64403751
Sepsis	103.92	14.10	196	15738	230145	64252653
Abdominal distension	92.13	14.10	116	15818	95878	64386920
Cystic fibrosis	74.29	14.10	29	15905	3405	64479393
Stress	72.64	14.10	82	15852	60452	64422346
Hepatic failure	61.34	14.10	72	15862	55322	64427476
Toxic epidermal necrolysis	54.51	14.10	56	15878	37110	64445688
Coagulopathy	54.03	14.10	52	15882	31868	64450930
Ventricular fibrillation	44.46	14.10	41	15893	23819	64458979
Respiratory failure	41.75	14.10	110	15824	161073	64321725
Hyponatraemia	40.23	14.10	103	15831	148236	64334562
Activated partial thromboplastin time prolonged	38.39	14.10	29	15905	12802	64469996
Abdominal pain	37.80	14.10	165	15769	312210	64170588
Hepatic encephalopathy	36.94	14.10	35	15899	21031	64461767
Acute hepatic failure	35.87	14.10	38	15896	26074	64456724
Haemoptysis	34.46	14.10	51	15883	48997	64433801
Renal vascular thrombosis	34.38	14.10	7	15927	70	64482728
Prothrombin time prolonged	33.18	14.10	29	15905	15712	64467086
Constipation	33.14	14.10	128	15806	229209	64253589
Hyperbilirubinaemia	33.00	14.10	33	15901	21172	64461626
Factor V inhibition	32.72	14.10	9	15925	348	64482450
Drug intolerance	32.69	14.10	4	15930	187988	64294810
Thrombocytopenia	32.41	14.10	125	15809	223676	64259122
Cytokine release syndrome	31.65	14.10	32	15902	20797	64462001
General physical health deterioration	31.10	14.10	116	15818	204309	64278489
Pain	30.07	14.10	57	15877	553454	63929344
Osteochondritis	27.92	14.10	5	15929	23	64482775
Toxicity to various agents	27.02	14.10	30	15904	363483	64119315
Hyper IgE syndrome	25.57	14.10	8	15926	487	64482311
Cholestasis	25.06	14.10	42	15892	44830	64437968
Transverse sinus thrombosis	23.80	14.10	8	15926	612	64482186
Cystic fibrosis related diabetes	23.44	14.10	6	15928	175	64482623
Hyphaema	23.37	14.10	8	15926	647	64482151
Drug ineffective	23.18	14.10	118	15816	840129	63642669
Coagulation time prolonged	22.89	14.10	11	15923	2135	64480663
Blood bilirubin increased	22.26	14.10	46	15888	57507	64425291
Cortical visual impairment	21.74	14.10	4	15930	22	64482776
Dizziness	21.04	14.10	47	15887	430116	64052682
Acute kidney injury	20.69	14.10	185	15749	449055	64033743
Sputum increased	20.01	14.10	12	15922	3623	64479175
Distal intestinal obstruction syndrome	19.71	14.10	7	15927	631	64482167
Subdural haematoma	19.46	14.10	29	15905	28025	64454773
Intestinal dilatation	19.40	14.10	10	15924	2254	64480544
Fall	19.21	14.10	47	15887	416779	64066019
Haematemesis	18.69	14.10	38	15896	46961	64435837
Epileptic encephalopathy	18.59	14.10	6	15928	404	64482394
Iatrogenic infection	18.21	14.10	4	15930	59	64482739
Pulmonary function test decreased	18.00	14.10	14	15920	6447	64476351
Restrictive cardiomyopathy	17.59	14.10	7	15927	864	64481934
Contraindicated product administered	17.11	14.10	3	15931	107826	64374972
Septic shock	16.99	14.10	61	15873	105376	64377422
Jugular vein thrombosis	16.93	14.10	11	15923	3820	64478978
Superior sagittal sinus thrombosis	16.82	14.10	7	15927	969	64481829
HER2 positive breast cancer	16.71	14.10	5	15929	262	64482536
Transaminases increased	16.49	14.10	35	15899	44559	64438239
Vomiting	16.46	14.10	208	15726	550909	63931889
Disseminated intravascular coagulation	16.38	14.10	29	15905	32319	64450479
Tumour lysis syndrome	16.29	14.10	22	15912	19418	64463380
Blood alkaline phosphatase increased	16.20	14.10	40	15894	56239	64426559
Vitamin K deficiency	15.63	14.10	6	15928	673	64482125
Jaundice	15.60	14.10	36	15898	48476	64434322
Neutropenic colitis	15.15	14.10	11	15923	4570	64478228
Pancreatitis chronic	15.13	14.10	10	15924	3576	64479222
Drug reaction with eosinophilia and systemic symptoms	15.04	14.10	38	15896	54179	64428619
Acute respiratory distress syndrome	14.91	14.10	31	15903	38904	64443894
Bacteraemia	14.77	14.10	25	15909	26886	64455912
Hepatorenal syndrome	14.73	14.10	10	15924	3736	64479062
Heparin-induced thrombocytopenia	14.69	14.10	14	15920	8465	64474333
Joint swelling	14.68	14.10	19	15915	215363	64267435
Lactobacillus test positive	14.64	14.10	3	15931	31	64482767
C-reactive protein decreased	14.35	14.10	8	15926	2108	64480690
Medical device site haemorrhage	14.15	14.10	4	15930	171	64482627
Gait disturbance	14.15	14.10	13	15921	172142	64310656

FDA Adverse Event Reporting System (Pediatric)

None

Pharmacologic Action:

Source	Code	Description
ATC	B02BA01	BLOOD AND BLOOD FORMING ORGANS ANTIHEMORRHAGICS VITAMIN K AND OTHER HEMOSTATICS Vitamin K
FDA CS	M0022806	Vitamin K
MeSH PA	D000933	Antifibrinolytic Agents
MeSH PA	D003029	Coagulants
MeSH PA	D006401	Hematologic Agents
MeSH PA	D006490	Hemostatics
MeSH PA	D018977	Micronutrients
MeSH PA	D014815	Vitamins
FDA PE	N0000175965	Increased Prothrombin Activity
FDA EPC	N0000175966	Warfarin Reversal Agent
FDA PE	N0000175982	Reversed Anticoagulation Activity
FDA EPC	N0000180191	Vitamin K
CHEBI has role	CHEBI:23357	cofactor
CHEBI has role	CHEBI:76924	plant metabolites
CHEBI has role	CHEBI:77746	Homo sapiens metabolite
CHEBI has role	CHEBI:24020	fat-soluble vitamins
CHEBI has role	CHEBI:75771	Mus musculus metabolites

Drug Use | Suggest Off label Use Form| |View source of the data|

Disease	Relation	SNOMED_ID	DOID
Hypocalcemia	indication	5291005
Osteoporosis	indication	64859006	DOID:11476
Factor II deficiency	indication	73975000
Postmenopausal osteoporosis	indication	102447009
Prevention of Neonatal Hemorrhagic Disease	indication
Antibiotic-Induced Hypoprothrombinemia	indication
Neonatal Hemorrhagic Disease	indication
Vitamin K Deficiency Induced Hypoprothrombinemia	indication
Anticoagulant-Induced Prothrombin Deficiency	indication
Obstruction of bile duct	off-label use	30144000
Abetalipoproteinemia	off-label use	190787008	DOID:1386
Constipation	contraindication	14760008	DOID:2089
Hyperphosphatemia	contraindication	20165001	DOID:0050459
Hypervitaminosis D	contraindication	27712000	DOID:9971
Sarcoidosis	contraindication	31541009	DOID:11335
Dehydration	contraindication	34095006
Vitamin E deficiency	contraindication	54137008
Hypercalcemia	contraindication	66931009	DOID:12678
Hyperparathyroidism	contraindication	66999008	DOID:13543
Diabetes mellitus	contraindication	73211009	DOID:9351
Kidney disease	contraindication	90708001	DOID:557
Kidney stone	contraindication	95570007
Anemia due to enzyme deficiency	contraindication	111577008
Neoplasm of endometrium	contraindication	123844007	DOID:1380
Neoplasm of prostate	contraindication	126906006	DOID:10283
Osteolysis	contraindication	203522001
Arteriosclerosis obliterans	contraindication	361133006	DOID:5160
Malignant tumor of cervix	contraindication	363354003	DOID:4362
Central nervous system depression	contraindication	418072004
Carcinoma of female breast	contraindication	447782002

🐶 Veterinary Drug Use

None

🐶 Veterinary products

None

Acid dissociation constants calculated using MoKa v3.0.0

None

Orange Book patent data (new drug applications)

None

Orange Book exclusivity data (new drug applications)

Formulation strength	Trade name	Applicant	Application number	Approval date	Type	Dose form	Route	Exclusivity date	Description
10MG/ML	PHYTONADIONE	CIPLA	A214596	April 22, 2022	RX	INJECTABLE	INJECTION	Oct. 30, 2022	COMPETITIVE GENERIC THERAPY
1MG/0.5ML	PHYTONADIONE	CIPLA	A214596	April 22, 2022	RX	INJECTABLE	INJECTION	Oct. 30, 2022	COMPETITIVE GENERIC THERAPY

Bioactivity Summary:

Target	Class	Pharos	UniProt	Action	Type	Activity value (-log[M])	Mechanism action	Bioact source	MoA source
Alpha-synuclein	Transporter	P37840	SYUA_HUMAN		IC50	4.82		CHEMBL

External reference:

ID	Source
4017772	VUID
N0000146136	NUI
D00148	KEGG_DRUG
4017772	VANDF
4018981	VANDF
4021719	VANDF
4021911	VANDF
C0031862	UMLSCUI
CHEBI:18067	CHEBI
PQN	PDB_CHEM_ID
CHEMBL1550	ChEMBL_ID
CHEMBL1201519	ChEMBL_ID
DB01022	DRUGBANK_ID
5284607	PUBCHEM_CID
11258	RXNORM
1433	MMSL
15677	MMSL
199215	MMSL
42273	MMSL
5298	MMSL
d03135	MMSL
001038	NDDF
001042	NDDF
63136007	SNOMEDCT_US
65183007	SNOMEDCT_US
66656000	SNOMEDCT_US
74226000	SNOMEDCT_US
D010837	MESH_DESCRIPTOR_UI
D014812	MESH_DESCRIPTOR_UI
177	INN_ID
A034SE7857	UNII

Pharmaceutical products:

Product	Category	Ingredients	NDC	Form	Quantity	Route	Marketing	Label
Mephyton	HUMAN PRESCRIPTION DRUG LABEL	1	0187-1704	TABLET	5 mg	ORAL	NDA	22 sections
Mephyton	HUMAN PRESCRIPTION DRUG LABEL	1	0187-1704	TABLET	5 mg	ORAL	NDA	22 sections
PHYTONADIONE	HUMAN PRESCRIPTION DRUG LABEL	1	0404-9935	INJECTION, EMULSION	1 mg	PARENTERAL	ANDA	16 sections
PHYTONADIONE	HUMAN PRESCRIPTION DRUG LABEL	1	0404-9969	INJECTION, EMULSION	10 mg	INTRAMUSCULAR	ANDA	12 sections
Vitamin K1	HUMAN PRESCRIPTION DRUG LABEL	1	0409-9157	INJECTION, EMULSION	2 mg	INTRAMUSCULAR	ANDA	18 sections
Vitamin K1	HUMAN PRESCRIPTION DRUG LABEL	1	0409-9158	INJECTION, EMULSION	10 mg	INTRAMUSCULAR	ANDA	18 sections
Phytonadione	HUMAN PRESCRIPTION DRUG LABEL	1	0904-6882	TABLET	5 mg	ORAL	ANDA	28 sections
Phytonadione	HUMAN PRESCRIPTION DRUG LABEL	1	0904-6882	TABLET	5 mg	ORAL	ANDA	28 sections
Phytonadione	HUMAN PRESCRIPTION DRUG LABEL	1	16714-973	TABLET	5 mg	ORAL	ANDA	21 sections
Phytonadione	HUMAN PRESCRIPTION DRUG LABEL	1	16714-973	TABLET	5 mg	ORAL	ANDA	21 sections
MEPHYTON	HUMAN PRESCRIPTION DRUG LABEL	1	21695-168	TABLET	5 mg	ORAL	NDA	21 sections
PHYTONADIONE PHYTONADIONE	HUMAN PRESCRIPTION DRUG LABEL	1	43598-405	INJECTION, EMULSION	10 mg	INTRAMUSCULAR	ANDA	19 sections
Mephyton	HUMAN PRESCRIPTION DRUG LABEL	1	50090-1753	TABLET	5 mg	ORAL	NDA	20 sections
Vitamin K1	HUMAN PRESCRIPTION DRUG LABEL	1	50090-4521	INJECTION, EMULSION	10 mg	INTRAMUSCULAR	ANDA	19 sections
Vitamin K1	HUMAN PRESCRIPTION DRUG LABEL	1	50090-4523	INJECTION, EMULSION	2 mg	INTRAMUSCULAR	ANDA	19 sections
Phytonadione	HUMAN PRESCRIPTION DRUG LABEL	1	50268-661	TABLET	5 mg	ORAL	NDA authorized generic	20 sections
VITAMIN K1 - PHYTONADIONE	HUMAN PRESCRIPTION DRUG LABEL	1	51662-1536	INJECTION, EMULSION	10 mg	INTRAMUSCULAR	ANDA	13 sections
VITAMIN K1 PHYTONADIONE	HUMAN PRESCRIPTION DRUG LABEL	1	51662-1537	INJECTION, EMULSION	2 mg	INTRAMUSCULAR	ANDA	13 sections
PHYTONADIONE	HUMAN PRESCRIPTION DRUG LABEL	1	52584-043	INJECTION, EMULSION	1 mg	PARENTERAL	ANDA	13 sections
PHYTONADIONE	HUMAN PRESCRIPTION DRUG LABEL	1	52584-046	INJECTION, EMULSION	1 mg	PARENTERAL	ANDA	16 sections
Phytonadione	HUMAN PRESCRIPTION DRUG LABEL	1	52584-240	INJECTION, EMULSION	1 mg	PARENTERAL	ANDA	13 sections
PHYTONADIONE	HUMAN PRESCRIPTION DRUG LABEL	1	52584-405	INJECTION, EMULSION	10 mg	INTRAMUSCULAR	ANDA	12 sections
PEDIATRIC INFUVITE MULTIPLE VITAMINS FOR INFUSION	HUMAN PRESCRIPTION DRUG LABEL	13	54643-5646	INJECTION, SOLUTION	0.20 mg	INTRAVENOUS	NDA	19 sections
Adult Infuvite Multiple Vitamins for Infusion	HUMAN PRESCRIPTION DRUG LABEL	13	54643-5649	INJECTION, SOLUTION	150 ug	INTRAVENOUS	NDA	17 sections
Adult Infuvite Multiple Vitamins for Infusion	HUMAN PRESCRIPTION DRUG LABEL	13	54643-5649	INJECTION, SOLUTION	150 ug	INTRAVENOUS	NDA	17 sections
Infuvite Adult Multiple Vitamins	HUMAN PRESCRIPTION DRUG LABEL	13	54643-5650	INJECTION, SOLUTION	150 ug	INTRAVENOUS	NDA	20 sections
Adult Infuvite Multiple Vitamins	HUMAN PRESCRIPTION DRUG LABEL	13	54643-7862	INJECTION, SOLUTION	150 ug	INTRAVENOUS	NDA	20 sections
Adult Infuvite Multiple Vitamins	HUMAN PRESCRIPTION DRUG LABEL	13	54643-7874	INJECTION, SOLUTION	150 ug	INTRAVENOUS	NDA	20 sections
Pediatric Infuvite Multiple Vitamins	HUMAN PRESCRIPTION DRUG LABEL	13	54643-7886	INJECTION, SOLUTION	0.20 mg	INTRAVENOUS	NDA	19 sections
Adult Infuvite Multiple Vitamins	HUMAN PRESCRIPTION DRUG LABEL	13	54643-9007	INJECTION, SOLUTION	150 ug	INTRAVENOUS	NDA	20 sections